Active PriorityDeveloping
Employer Coverage for GLP-1 Weight Loss Drugs Stagnates Amid Soaring Costs
worth trackingUpdated 2h ago
Key takeaway: The stagnation in employer coverage for GLP-1 weight loss drugs highlights the tension between medical innovation, patient demand, and economic sustainability in the American healthcare system.
